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ABSTRACT Campylobacter jejuni is a foodborne pathogen that is recognized as the
leading cause of human bacterial gastroenteritis. The widespread use of antibiotics
in medicine and in animal husbandry has led to an increased incidence of antibiotic
resistance in Campylobacter. In addition to a role in multidrug resistance (MDR), the
Campylobacter CmeABC resistance-nodulation-division (RND)-type efﬂux pump may
be involved in virulence. As a vehicle for pathogenic microorganisms, the protozoan
Acanthamoeba is a good model for investigations of bacterial survival in the envi-
ronment and the molecular mechanisms of pathogenicity. The interaction between
C. jejuni 81-176 and Acanthamoeba polyphaga was investigated in this study by us-
ing a modiﬁed gentamicin protection assay. In addition, a possible role for the Cme-
ABC MDR pump in this interaction was explored. Here we report that this MDR
pump is beneﬁcial for the intracellular survival and multiplication of C. jejuni in A.
polyphaga but is dispensable for bioﬁlm formation and motility.
IMPORTANCE The endosymbiotic relationship between amoebae and microbial
pathogens may contribute to persistence and spreading of the latter in the environ-
ment, which has signiﬁcant implications for human health. In this study, we found
that Campylobacter jejuni was able to survive and to multiply inside Acanthamoeba
polyphaga; since these microorganisms can coexist in the same environment (e.g.,
on poultry farms), the latter may increase the risk of infection with Campylobacter.
Our data suggest that, in addition to its role in antibiotic resistance, the CmeABC
MDR efﬂux pump plays a role in bacterial survival within amoebae. Furthermore, we
demonstrated synergistic effects of the CmeABC MDR efﬂux pump and TetO on bac-
terial resistance to tetracycline. Due to its role in both the antibiotic resistance and
the virulence of C. jejuni, the CmeABC MDR efﬂux pump could be considered a good
target for the development of antibacterial drugs against this pathogen.
KEYWORDS Campylobacter jejuni, Acanthamoeba polyphaga, host cell invasion,
survival and multiplication, antibiotic resistance, multidrug efﬂux pumps, bioﬁlm
formation, motility, CmeB
Campylobacter jejuni is a microaerophilic, spiral-shaped, Gram-negative, motile, food-borne pathogen that is recognized as the main cause of bacterial gastroenteritis
worldwide (1). Most commonly, the disease is associated with consumption of under-
cooked poultry or contaminated water, where Campylobacter can coexist with protozoa
and form bioﬁlms (2). Antimicrobial therapy is warranted for immunocompromised
patients or patients with severe infections and, although most people recover quickly
from this disease, others may develop rare neurodegenerative disorders such as
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Guillain-Barré syndrome (GBS), which manifests as paralysis, requiring extensive med-
ical treatment (3).
The ability of C. jejuni to invade host cells is important for pathogenicity (4). To
establish infection in humans, C. jejuni invades the gut epithelial layer and colonizes the
intestine by employing a variety of virulence factors (2). The CmeABC multidrug
resistance (MDR) efﬂux pump plays a key role in C. jejuni colonization of chickens (a
natural host and a major reservoir of Campylobacter) by mediating resistance to bile
salts present in the intestinal tract (5). The MDR pump is a tripartite efﬂux system
belonging to the resistance-nodulation-division (RND) superfamily of bacterial trans-
porters. It consists of three components, i.e., the outer membrane channel-forming
protein CmeC, the inner membrane drug transporter CmeB, and the periplasmic
protein CmeA, which bridges CmeB and CmeC (6). The CmeABC complex contributes
to the intrinsic resistance of C. jejuni to a broad range of antibiotics, heavy metals, and
other antimicrobial agents (7). There are high levels of variation in the amino acid
sequences of the CmeB protein among C. jejuni strains, which may have an impact on
the function of this transporter (8). Investigation of the molecular mechanisms of
antibiotic resistance is important for control of the dissemination of multidrug-resistant
bacteria (9).
Although most studies of MDR pumps have focused on investigations of their role
as antibiotic resistance determinants, MDR pumps may also play a role in bacterial
pathogenesis (10–15). For example, the CmeB homologues AcrB (Salmonella enterica
and Klebsiella pneumoniae) and MexB (Pseudomonas aeruginosa) are required for inva-
sion of host cells and virulence (16–19), suggesting a possible contribution of the CmeB
protein to the pathogenic properties of C. jejuni.
The CmeABC efﬂux pump of C. jejuni is known to be required for resistance to
antibiotics, bile salts, and some disinfectants, as well for host colonization (5, 7, 20).
However, its role in bioﬁlm formation, motility, or survival within amoebae has not yet
been studied.
Acanthamoeba is a genus of amoebae containing free-living protist pathogens that
are widely spread in water environments (21, 22). These eukaryotic organisms are
characterized by spine-like structures on their surface, which allows them to adhere, to
move, and to capture their prey by phagocytosis (21). During their life cycle, acan-
thamoebae can adopt two reversible forms, i.e., trophozoite cells, which are able to
feed on microbes, and dormant, double-walled, cyst cells with minimal metabolic
activity, which are formed under adverse environmental conditions such as extreme
temperatures or pH values (22). Acanthamoebae are opportunistic pathogens that are
capable of causing serious human infections, including blinding keratitis, which is
associated mostly with contact lens users, and fatal granulomatous encephalitis, which
occurs mainly in immunocompromised patients (21).
An increasing number of microorganisms, such as bacteria and viruses, have been
reported to beneﬁt from interactions with these free-living pathogens, as the amoebae
play a role as a reservoir, allowing the microorganisms to escape predation and perhaps
enabling them to survive and/or to multiply inside their hosts and to be transmitted in
the environment (23). Pathogenic microorganisms residing inside amoebae become
more virulent and less susceptible to antibiotics and disinfectants, making it difﬁcult to
eradicate them from public water supplies and creating problems for human and
animal health (24–26).
Amoebae are easy to handle experimentally and represent an attractive and simple
model of infection to study host-pathogen interactions in vitro, allowing the discovery
of new bacterial virulence factors, which may facilitate the development of new
antibacterial therapeutic agents (27). Also, amoebae exhibit features similar to those of
macrophages, especially in the way they capture their prey by phagocytosis (28).
Elucidation of the molecular mechanisms involved in these interactions is relevant
to public health, since microbial pathogens and acanthamoebae can coexist in the
same environments, e.g., in the water of industrial poultry houses (despite stringent
biosecurity measures) (29). Such associations may be beneﬁcial to the acanthamoebae
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and/or the bacteria, which may lead to symbiotic relationships between these micro-
organisms (30).
The molecular mechanisms of interactions between C. jejuni and these eukaryotic
hosts are not well understood. The results from a few publications describing the
interactions between Acanthamoeba polyphaga and C. jejuni are contradictory (31).
While some studies suggest the ability of C. jejuni to survive and/or to multiply within
amoebae (32–39), others support an extracellular mode of survival only (40–43). These
conﬂicting results may be explained by variations in the strains of C. jejuni and amoebae
and the use of different methods, such as whether the in vitro survival experiments
involved gentamicin treatment.
The objectives of this study were (i) to elucidate the type of interactions between C.
jejuni and A. polyphaga, (ii) to investigate whether the CmeB multidrug efﬂux trans-
porter is involved in this interaction, (iii) to explore other possible biological functions
for this transporter in C. jejuni, and (iv) to investigate the contribution of variations in
the amino acid sequence encoded by cmeB to the tetracycline resistance of C. jejuni. To
accomplish the ﬁrst two aims, the standard gentamicin protection method was mod-
iﬁed to ensure more efﬁcient elimination of both attached and extracellular bacteria
(which could escape to the medium and cause reinfection, thus potentially producing
misleading data).
The association between foodborne pathogens and protozoa leads to serious
consequences for food safety, increasing the risk of infection (44). Deciphering the
molecular mechanisms of Campylobacter-amoeba interactions will facilitate a better
understanding of the lifestyle of this foodborne pathogen, aiding in the development
of novel intervention strategies.
RESULTS
C. jejuni 81-176 is able to survive and to multiply within A. polyphaga. The
survival of C. jejuni at different temperatures was investigated in vitro by using the A.
polyphaga model of infection. Due to its lifestyle, Campylobacter is likely to encounter
a wide range of environmental conditions, including different temperatures. In order to
survive, it must be able to sense, to adapt to, and to respond to temperature ﬂuctu-
ations (45). The temperatures 25°C and 37°C were selected for this study, to mimic
environmental and human host temperatures, respectively.
To elucidate the interaction between C. jejuni 81-176 and A. polyphaga, the standard
gentamicin protection method (19) was modiﬁed by adding an extra 1 h of gentamicin
treatment at the later incubation time points, before lysis of the cells; this avoided
quantiﬁcation of bacteria that were attached or had escaped to the extracellular
medium and that were potentially capable of reinvasion, since the gentamicin concen-
tration used (100 g/ml) was sufﬁcient to kill C. jejuni wild-type (WT) and mutant strains
(data not shown). By using the modiﬁed version of this method, we observed a
substantial decrease in the numbers of intracellular bacteria, compared with the
standard version, at both 25°C (Fig. 1A) and 37°C (Fig. 1B).
At 25°C and 0 h (deﬁned as the time point immediately after the ﬁrst gentamicin
treatment), the methods produced similar CFU counts (Fig. 1A). However, much greater
decreases in intracellular bacteria were observed at 5 h and 24 h with the modiﬁed
procedure (Fig. 1A). Since no colonies were detectable at this temperature after 48 h
(data not shown), no further time points are shown. These data indicate that strain
81-176 can invade and survive inside amoebae at 25°C for a certain period.
Because the optimal growth temperature for C. jejuni is 37°C, time points for this
temperature were extended to 72 h. At this temperature, the decrease in the intracel-
lular bacterial numbers at 24 h after gentamicin treatment with the modiﬁed genta-
micin method was even more pronounced, and even greater differences were observed
at the later time points (Fig. 1B). With both methods, initial reductions in the CFU
counts were followed by increases after prolonged incubation, suggesting bacterial
multiplication (Fig. 1B). Although the methods demonstrated the same trends in
Biological Activity of C. jejuni CmeABC Applied and Environmental Microbiology
November 2017 Volume 83 Issue 22 e01600-17 aem.asm.org 3
 o
n
 D
ecem
ber 19, 2017 by KING
STO
N UNIVERSITY
http://aem
.asm
.org/
D
ow
nloaded from
 
changes in CFU counts with time, the modiﬁed version allowed more accurate quan-
tiﬁcation of only intracellular bacteria and was used in all subsequent experiments.
A different modiﬁcation of the gentamicin protection method, in which a lower
concentration of gentamicin is constantly maintained, was described elsewhere (46).
Using that method, however, we observed that C. jejuni 81-176 was not able to multiply
intracellularly and was not detected 48 h postinfection (data not shown), probably
because the antibiotic was able to enter the amoebic cells during prolonged incuba-
tions. This observation is in accordance with previous studies reporting the ability of
gentamicin to enter host cells during prolonged incubations and to kill intracellular
bacteria (47, 48).
The numbers of viable extracellular bacteria were monitored for a 6-day period. At
96 h postinfection, a signiﬁcant increase in bacterial counts was observed, compared
with bacteria incubated in medium alone. Moreover, after 6 days of incubation, the
presence of amoebae allowed the isolation of viable bacteria, while none could be
detected in the absence of amoebae (see Fig. S1 in the supplemental material). In
summary, these data support both extracellular and intracellular modes of survival for
C. jejuni 81-176 in cocultures with A. polyphaga at different temperatures.
FIG 1 C. jejuni 81-176 is able to survive and to multiply inside A. polyphaga. (A) Intracellular survival was
determined by CFU counting at 0, 5, and 24 h after gentamicin treatment at 25°C, under aerobic
conditions. (B) Intracellular multiplication was determined at 0, 24, 48, and 72 h after gentamicin
treatment at 37°C, under aerobic conditions. Black bars represent bacterial counts obtained with the
standard gentamicin protection assay, and gray bars represent bacterial counts obtained with a modiﬁed
version developed in this study. P values, referring to comparisons between the samples at each time
point, were as follows: panel A: 0 h, P  0.583; 5 h, P  0.031; 24 h, P  0.00003; panel B: 0 h, P  0.166;
24 h, P  0.03; 48 h, P  0.001; 72 h, P  0.00028. *, 0.01  P  0.05; **, 0.001  P  0.01; ***, P  0.001.
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CmeB contributes to C. jejuni 81-176 intracellular survival and multiplication
within A. polyphaga. To check whether the C. jejuni CmeB transporter is required for
survival and multiplication within amoebae, the cmeB gene of strain 81-176 was
inactivated by insertional mutagenesis (49) to create the 81-176/cmeB::kanr mutant.
Complementation was achieved by replacement of the mutated gene with its wild-type
copy and selection of the derivative at a tetracycline concentration that did not support
the growth of the mutant strain (Table 1). Construction of the mutant strain and its
complementation derivative was conﬁrmed by PCR (Fig. S2A). The mutation had no
impact on the bacterial growth rate (Fig. S2B).
The tissue culture experiments involved lysis of the amoebic cells with 0.1% Triton
X-100 for 15 min at room temperature. Because the 81-176 cmeB mutant strain was
shown to be susceptible to this detergent (5), experiments were performed to ensure
that the data obtained were genuine and not experimental artifacts. The effect of 0.1%
(vol/vol) Triton X-100 was investigated by simulating its use in cell culture experiments
in which this detergent was added to the bacteria for a short period. Under those
conditions, CFU counts for the 81-176/cmeB::kanr mutant were similar to those of the
WT and complemented strains (Fig. S3), suggesting that Triton X-100 had no detrimen-
tal effect on bacterial viability.
At both 25°C and 37°C, the numbers of intracellular bacteria for the 81-176/cmeB::
kanr mutant were signiﬁcantly lower than those of the wild-type strain, with the
difference increasing after longer incubations (Fig. 2A). In contrast to the WT strain, no
ampliﬁcation of bacteria was observed at 37°C even after 72 h (Fig. 2B). There was no
statistically valid difference in CFU numbers for the mutant at 48 h and 72 h, compared
to those at 24 h (P  0.24 and P  0.09, respectively). Complementation of the 81-176
cmeB mutant strain restored the phenotype in all experiments. In summary, the results
suggest that the C. jejuni 81-176 CmeB is required for bacterial survival and multipli-
cation in acanthamoebae.
CmeB is not required for bioﬁlm formation and motility of C. jejuni 81-176. The
ability to form bioﬁlms is an important factor in the lifestyle of C. jejuni (50). Some
studies showed that inactivation of the multidrug efﬂux pumps could prevent bioﬁlm
formation (51). Using a previously described assay to study pellicle formation at the
air-liquid interface (52), we found no effect of the cmeB mutation on the ability of the
bacteria to form this type of bioﬁlm (Fig. 3A). Since C. jejuni motility plays an important
role in the invasion of host cells (53), we also aimed to verify whether mutated bacteria
remained motile. As shown in Fig. 3B, the cmeB mutation did not have any effect on
bacterial motility.
The CmeABC transporter and sequence variations of the CmeB protein con-
tribute to tetracycline resistance. The tetracycline resistance of some Campylobacter
strains is associated with the tetO gene carried by a pTet plasmid (6). In a previous
study, we observed that C. jejuni strain G1, which was isolated from a patient with GBS,
was more resistant to tetracycline than was the 11168H strain, despite the absence of
TABLE 1 Susceptibility of C. jejuni WT strains and their cmeB mutants to tetracycline
Campylobacter jejuni strain
Tetracycline MIC
(mean  SD) (g/l)a
Fold change
(WT strain vs mutant strain)
81-176/cmeB/pTet (WT) 62.5 0.010
81-176/cmeB/pTet 7.8 0.020 8
11168H/cmeB/pTet (WT) 0.12 0.017
11168/cmeB/pTet 0.06 0.017 2
G1/cmeB/pTet (WT) 1.95 0.002
G1/cmeB/pTet 0.06 0.011 32.5
G1/cmeB/pTet 500 0.031 256
aMICs for tetracycline were determined by the microdilution method in MH-F broth, according to the
EUCAST recommendations (64). Tetracycline MICs were determined for strains 81-176, 11168H, and G1 and
their respective cmeB mutants; three clonal isolates were tested for each strain. The tetracycline MIC value
was also determined for a derivative of the G1 strain containing the pTet plasmid from C. jejuni strain
81-176.
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the tetO gene in both strains (54). Comparison of the genome of the G1 strain with that
of reference strain NCTC 11168 revealed a remarkable difference in the sequences of
the cmeB genes (54). The protein sequence identity for cmeB genes from these two
strains was only 81%, while that for genes from strains 11168H and 81-176 was as high
as 99%. In this study, we found that inactivation of cmeB in the G1 strain resulted in
greater reduction of resistance to tetracycline than did inactivation of cmeB in the
11168H strain (Table 1). However, transfer of the pTet plasmid from C. jejuni 81-176 to
the G1 strain by conjugation made the latter 8 times more resistant to tetracycline than
the donor C. jejuni 81-176 carrying this plasmid (Table 1). This ﬁnding suggests that the
CmeABC MDR efﬂux pump of C. jejuni strain G1 has greater ability to excrete this drug
than do those of C. jejuni strains 11168H and 81-176. Since the nucleotide sequence
differences were predominantly limited to cmeB, the variation in the efﬁciency of these
pumps may be primarily associated with the product of this gene (Tables S1 and S2).
In addition, it was found that C. jejuni strain G1 was more resistant than strain 81-176
to various antibiotics and that the disruption of cmeB (conﬁrmed with three clonal
isolates) increased the susceptibility of the G1 strain to almost all antibiotics tested. The
FIG 2 CmeB is required for survival and multiplication of C. jejuni 81-176 in A. polyphaga. (A) Intracellular
survival was determined by CFU counting at 0, 5, and 24 h after gentamicin treatment at 25°C, under
aerobic conditions. (B) Intracellular multiplication was determined at 0, 24, 48, and 72 h after gentamicin
treatment at 37°C, under aerobic conditions. Black bars, 81-176; white bars, 81-176/cmeB::kanr mutant;
gray bars, 81-176/cmeB::kanr/cmeB complementation derivative. P values, referring to comparisons
between the values for WT and mutant strains at each time point, were as follows: panel A: 0 h, P 0.018;
5 h, P  0.015; panel B: 0 h, P  0.021; 24 h, P  0.031; 48 h, P  0.028; 72 h, P  0.000004. *, 0.01 
P  0.05; ***, P  0.001. ND, not detected.
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exceptions were penicillin, linezolid, and trimethoprim, for which no difference could
be found due to very low (undetectable) levels of inhibition, probably due to low
concentrations of the antibiotics used (Fig. S4). These data show that the spectrum and
level of antimicrobial resistance of C. jejuni may be primarily dependent on the
sequence variations of cmeB, with the potential for certain mutations in this gene to
result in “super” efﬂux pump variants, signiﬁcantly enhancing bacterial resistance to
multiple antibiotics.
DISCUSSION
The association between free-living amoebae and pathogenic bacteria is concern-
ing, because it may have signiﬁcant implications for human health (55). In this study,
the interaction between C. jejuni 81-176 and A. polyphaga was investigated. C. jejuni
displays extensive genetic variation; consequently, the efﬁciency by which C. jejuni
interacts with cultured cells depends on speciﬁc properties of the strains (2, 56).
This study suggests that, during longer periods of incubation with A. polyphaga at
37°C, intracellular C. jejuni may escape into the extracellular medium, multiply, and
reinfect amoebic cells. As the result, reinfection rather than intracellular multiplication
FIG 3 The cmeB mutation does not affect bioﬁlm formation and motility. (A) Quantiﬁcation of bioﬁlms
at the air-liquid interface of the glass tubes. The absorbance values measured for the WT, cmeB mutant,
and complemented strains were 0.179  0.06, 0.151  0.01, and 0.145  0.02, respectively. No
statistically signiﬁcant difference (P  0.443) in bioﬁlm quantities between the WT and cmeB mutant
strains was observed. (B) Quantiﬁcation of growth zones in BHI soft-agar motility plates inoculated with
different C. jejuni strains. The average diameters of bacterial growth for the WT, cmeB mutant, and
complemented strains were 34.2  6.37 mm, 26.7  3.33 mm, and 32.2  4.54 mm, respectively. No
statistically signiﬁcant difference in growth zones (P  0.15) between the WT and cmeB mutant strains
was observed. Black bars, 81-176; white bars, 81-176/cmeB::kanr mutant; gray bars, 81-176/cmeB::kanr/
cmeB complementation derivative.
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may be the primary factor responsible for increased intracellular numbers. In order to
obtain more accurate data about intracellular multiplication, an additional gentamicin
treatment step was introduced in this study. Compared with the standard gentamicin
assay, much more signiﬁcant reductions in intracellular bacterial numbers were ob-
served at both 25°C and 37°C. In the future, it would be interesting to investigate the
interaction between C. jejuni and A. polyphaga at 42°C, as this is the chicken body
temperature. It was observed previously that, at that temperature, the amoebic cells
changed to the cyst shape (21). This is relevant, since amoebic cysts may play a role in
contamination and the persistence of pathogenic bacteria in food-related environ-
ments, allowing internalized foodborne pathogens to resist the disinfection treatments
used in the food industry (57). Despite gradual decreases in the numbers of intracellular
bacteria at 25°C, the fact that intracellular bacteria are still detectable after 24 h might
be of epidemiological importance if the amoebae are constantly exposed to the
presence of these bacteria in the environment.
Our data also demonstrated prolonged extracellular survival of strain 81-176 in the
presence of amoebae, which is in accordance with previously published results (41).
According to Bui et al., this is likely to be due to the depletion of dissolved oxygen by
amoebae, thus creating the microaerophilic environment optimal for C. jejuni growth
(41).
At 37°C, the initial decrease in the number of viable bacteria was followed by a
remarkable increase after 48 h of incubation. A similar trend was reported for S. enterica
and Listeria monocytogenes (58). The authors termed the initial decrease in viability the
eclipse phase, which probably occurs due to the initial use of the bacteria as a food
source or due to a prolonged lag or adaptation phase, followed by active intracellular
growth (58).
Although the CmeABC efﬂux pump of C. jejuni was reported previously to be
required for colonization of the intestinal tract of chickens (5), its role in bacterium-host
cell interactions was not determined. We were able to show that this pump is beneﬁcial
for the survival and replication of C. jejuni 81-176 within amoebae and that the
reduction in the CFU numbers for the cmeB mutant was not the result of its greater
sensitivity to the detergent used for amoebic lysis. These observations support the idea
that efﬂux pumps may indeed act as virulence determinants. The role of MDR efﬂux
pumps in virulence could be linked to their ability to expel and to confer resistance to
host-derived antimicrobial agents, such as low-molecular-weight toxins (reactive oxy-
gen species) and antimicrobial peptides (14).
Based on the information available in the literature and the data presented here, we
suggest a hypothetical model describing a mechanism of interaction between C. jejuni
and the amoebae (Fig. 4). According to this model, intracellular bacteria acquired from
the environment (e.g., at 25°C, as in our experiments) multiply at 37°C (conditions
simulating the host temperature). After ingestion of a product (e.g., water or milk)
contaminated with amoebae, the latter are lysed, releasing large amounts of bacteria
causing disease. A global search for other bacterial factors involved in the interaction
between C. jejuni and amoebae could be based on differential expression studies
(transcriptomics and proteomics). Our data also suggested that neither motility nor
bioﬁlm formation was responsible for the decreased survival of the cmeB mutant strain
within the A. polyphaga host.
As demonstrated in this study, the exchange of genetic elements involved in
antibiotic resistance can result in dramatic elevation of C. jejuni resistance to antibiotics.
This is in accordance with other studies reporting C. jejuni CmeB sequence variants with
much more powerful efﬂux of antibiotics, leading to enhanced antibiotic resistance (8,
59). The CmeB from C. jejuni strain G1 in this study shared 99% identity with the two
super efﬂux pump variants discovered previously, i.e., the 154KU variant (8) and the
RE-CmeB variant (59), suggesting that the CmeB from the G1 strain might also be a
super efﬂux variant. However, this hypothesis needs to be supported by further studies.
Despite much greater strain-to-strain sequence variation of CmeB, compared with other
components of the MDR pump and CmeR, further experiments are required for
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evaluation of the relative contributions of these proteins to variations in the levels of
antibiotic resistance. In this study, it was possible to generate bacteria with tetracycline
resistance levels remarkably exceeding those of all parental strains. Such exchanges are
likely to occur in the environment not only via conjugation (e.g., involving a transfer of
the pTet plasmid) but also via transformation, as many strains of C. jejuni are naturally
competent and can easily acquire DNA released due to the lysis of cells carrying
antibiotic resistance genes (2). As a result, originally sensitive C. jejuni strains might
easily become more resistant to antibiotics. Variation in CmeB structure is just one of
various strategies utilized by bacteria for adaptation to hostile environmental condi-
tions, both in vivo and ex vivo.
To summarize, we describe here the contribution of a Campylobacter efﬂux pump to
bacterial survival within amoebae, which was demonstrated by employing an improved
gentamicin protection method. Moreover, using a modiﬁed version of the gentamicin
FIG 4 Hypothetical model of the interaction between C. jejuni and A. polyphaga. The following possible stages of bacterial entry are
depicted: 1, adhesion to and invasion of amoebic cells via phagocytosis; 2, gathering within amoebic vacuoles (38, 40); 3, escape to the
extracellular (EC) medium (39); 4a, bacterial cell lysis; 4b, intracellular survival (ICS) and escape without lysis; 4c, intracellular multiplication
(ICM); 4d, escape after lysis followed by release into the extracellular medium (39); 5, presence in the extracellular medium. In the
extracellular medium, C. jejuni is able to multiply and to reinfect other amoebic cells. Stages 1, 3, 4a to 4c, and 5 are based on the
observations reported in this study.
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treatment method, the results explain the previously reported controversial results
from investigations of Campylobacter-amoeba interactions. Because CmeABC is re-
quired for C. jejuni antibiotic resistance and virulence, this efﬂux pump is a promising
target for interventions to combat C. jejuni infections.
MATERIALS AND METHODS
Bacterial strains and growth conditions. C. jejuni strain 81-176 was used throughout this study
because of its high virulence (60, 61) and enhanced ability to invade and to survive within A. polyphaga
(according to our data). C. jejuni 11168H, a hypermotile variant of the reference strain NCTC 11168 (62),
and G1, a strain isolated from a patient with Guillain-Barré syndrome (63), were used for the tetracycline
resistance assay. Strain X was isolated from a patient with enteritis (49). C. jejuni strains were routinely
grown for 24 h at 37°C on Columbia blood agar (CBA) (Oxoid) supplemented with 5% deﬁbrinated horse
blood and Campylobacter selective supplement (Skirrow; Oxoid), under microaerobic conditions (5% O2
and 10% CO2 in N2). NEB Express competent Escherichia coli used for molecular cloning was grown at
37°C in Luria-Bertani (LB) medium (Oxoid). When appropriate, the following antibiotics were included in
the culture medium as selective agents: ampicillin (100 g/ml), kanamycin (50 g/ml), and tetracycline
(10 g/ml).
For liquid cultures, C. jejuni was suspended in brain heart infusion (BHI) broth (Oxoid) and adjusted
to an optical density at 600 nm (OD600) of 1. The bacterial suspension was diluted 100-fold in BHI broth,
in sterile conical ﬂasks, and was incubated microaerobically at 37°C for 2 days, with shaking at 200 rpm.
One-milliliter samples of each bacterial culture were taken at each time point (0, 6, 24, 30, and 48 h), and
the OD600 was measured.
Generation of C. jejuni 81-176 cmeB mutant and complemented strains. Inactivation of the C.
jejuni 81-176 gene cmeB was achieved by an insertional mutagenesis approach (49), in which cmeB was
disrupted by insertion of a kanamycin resistance (kanr) cassette. The primers CmeB-F (5=-AAGGAGATAT
ACCATGTTTTCTAAATTTTTTATAGAAAGACCTATTTTTG-3=) and CmeB-R (5=-TCATTCATGAATCTTACCTCTTT
TTTTATCTAGC-3=) were used to amplify a 3-kb fragment containing the cmeB gene from C. jejuni 81-176
chromosomal DNA. The PCR product was ligated with pGEM-T Easy vector (Promega) using T4 DNA
ligase (New England BioLabs), followed by transformation into NEB Express competent E. coli and
selection of recombinant clones. The kanr cassette was isolated from vector pJMK30 by digestion with
SmaI (1.5 kb), followed by gel extraction of the 1.5-kb fragment containing the kanr cassette. The plasmid
pGEM-T Easy/cmeB was digested with ClaI and ligated with a DNA fragment containing the kanr cassette
by using T4 DNA ligase (Promega). After transformation of E. coli with the ligation mixture, the pGEM-T
Easy/cmeB::kanr plasmid containing the insert of interest, in the correct orientation, was isolated. The
pGEM-T Easy/cmeB::kanr plasmid was transformed into C. jejuni 81-176 via electroporation, and trans-
formants were selected on CBA supplemented with kanamycin (50 g/ml). The C. jejuni 81-176/cmeB::
kanr mutants were conﬁrmed by PCR analysis.
The complemented strain C. jejuni 81-176/cmeB::kanr/cmeB was constructed via homologous
recombination. The genomic DNA from the C. jejuni 81-176 strain was transformed into competent
cells of the cmeB mutant strain via electroporation, and transformants were selected in CBA
supplemented with tetracycline at 20 g/ml, a concentration that does not support the growth of
the cmeB mutant strain. A similar procedure was used for the construction of complementation
derivatives of other strains (Table 1).
Antibiotic susceptibility assays. (i) Broth microdilution assay. The MICs were determined accord-
ing to EUCAST guidelines (64). The MICs of tetracycline (Sigma) for C. jejuni strains were determined by
a broth microdilution method, using Mueller-Hinton-fastidious (MH-F) broth (cation-adjusted Mueller-
Hinton [MH] broth with 5% lysed blood and 20 mg/liter -NAD). Brieﬂy, 10 l of C. jejuni suspension in
MH-F broth (OD600 of 0.5) was added to 90 l of 2-fold dilutions of tetracycline in MH-F broth.
Suspensions were transferred to a 96-well ﬂat-bottomed microtiter plate (Corning) and incubated for 3
days at 37°C under microaerobic conditions, with shaking at 100 rpm. The tetracycline concentration
range tested was 0.03 g/ml to 500 g/ml, and control wells with no tetracycline were included. MICs
were measured at 600 nm using an Inﬁnite 200 PRO plate reader (Tecan). According to EUCAST
guidelines, the tetracycline MIC breakpoints for C. jejuni are as follows: sensitive, 2 g/l; resistant, 2
g/l (64).
(ii) Antibiotic disc diffusion assay. The antibiotic susceptibility of C. jejuni strains was determined
according to the EUCAST recommendations (64). C. jejuni was grown on CBA plates for 24 h at 37°C and
suspended in 1 ml of MH broth at an OD600 of 0.5. The suspension (100 l) was spread on MH agar plates
supplemented with 5% lysed horse blood, using a spreader. Antibiotic-containing discs (Oxoid) were
placed at the surface of the agar plates using sterile tweezers, and the plates were incubated for 2 days
at 37°C under microaerobic conditions. Inhibition zone diameters were measured and interpreted
accordingly to EUCAST zone diameter breakpoints for 30-g tetracycline discs, as follows: sensitive, 30
mm; resistant, 30 mm (64).
Amoebic culture conditions. Acanthamoeba polyphaga (Linc Ap-1), which was used in all
experiments, was kindly provided by Bernard de La Scola, University de La Mediterranee (Marseille,
France). A. polyphaga was maintained aerobically at 25°C in peptone-yeast-glucose (PYG) medium
(20 g protease peptone, 18 g glucose, 1 g yeast extract, 1 g MgSO4·7H2O, 1 g sodium citrate·2H2O,
0.02 g Fe(NH4)2(SO4)2·6H2O, 0.06 g CaCl2, 0.14 g H2PO4, and 0.35 g Na2HPO4·7H2O in 1 liter [pH 6.8];
ﬁlter sterilized with a 0.22-m ﬁlter), in 75-cm2 treated culture ﬂasks. The concentration and viability
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of amoebae were determined by the trypan blue exclusion assay, and amoebae were visualized by
phase-contrast microscopy with a 40 objective in an inverted cell culture microscope (Motic AE31).
To test the sensitivity of the C. jejuni 81-176 cmeBmutant to 0.1% (vol/vol) Triton X-100, bacterial cells
were harvested from overnight CBA plates, suspended in BHI medium, and adjusted to an OD600 of 1
(initial inoculum). As controls, 100-l aliquots of the initial inocula were serially diluted in phosphate-
buffered saline (PBS) and plated on CBA plates for CFU counting. The bacterial suspensions were then
centrifuged for 2 min at 10,000  g, 1 ml of 0.1% (vol/vol) Triton X-100 was added, and the cells were
incubated for 15 min at room temperature. Bacterial suspensions in Triton X-100 detergent were serially
diluted in PBS and plated on CBA plates. The CFU counts obtained for the mutant strain were compared
with those obtained for the WT and complemented strains.
In vitro coculture assay. Coculturing of C. jejuni with attached monolayers of A. polyphaga cells was
conducted in 24-well plates. A. polyphaga cells were seeded at a density of 106 amoebae per ml in PYG
medium and were incubated at 25°C for 2 h to allow the cells to settle and to form monolayers at the
bottom of the wells. Bacterial cells were harvested from overnight CBA plates, suspended in PYG
medium, and adjusted to an OD600 of 1. Then, 100 l of bacterial suspension was added to the wells with
A. polyphaga, achieving multiplicities of infection ranging from 100 to 400 bacteria per well. To allow
invasion to occur, cocultures were incubated under aerobic conditions for 2 h at 25°C or 37°C. Following
coincubation, wells were washed once with PYG medium and treated for 1 h with 100 g/ml gentamicin;
this concentration was shown to be effective in fully eliminating the bacterial cells in 1 h (data not
shown). Following gentamicin treatment, the wells were washed three times with PBS, and the amoebae
were lysed with 0.1% (vol/vol) Triton X-100 for 15 min at room temperature, releasing the intracellular
C. jejuni. Samples were serially diluted in PBS and plated on CBA plates, in duplicate, followed by 2 days
of incubation at 37°C under microaerobic conditions. For longer incubations (24, 48, and 72 h), the wells
were incubated with PYG medium without gentamicin. At the designated time points, prior to the
addition of 0.1% Triton X-100, the wells were retreated with gentamicin (100 g/ml) for 1 h (in a
modiﬁcation of the standard gentamicin protection assay). Cells were washed three additional times with
PBS, lysed, diluted, and plated as described above. To calculate the number of intracellular bacteria, the
following formula was used: [(recovered C. jejuni [in CFU per milliliter])/(total C. jejuni [in CFU per
milliliter])]  100  % intracellular C. jejuni in A. polyphaga.
Bioﬁlm formation assay. C. jejuni was grown on CBA plates at 37°C for 24 h, suspended in BHI broth,
and adjusted to an OD600 of 0.5. The bacterial suspension (1 ml) was transferred to borosilicate glass
tubes and incubated statically at 37°C for 4 days under microaerobic conditions, after which an attached
pellicle at the gas-liquid interface was observed (52). For crystal violet (CV) staining, the glass tubes were
washed twice with distilled water and dried at 85°C for 30 min. Then, 0.5% CV solution was added to the
tubes, and the tubes were incubated at room temperature for 30 min, with gentle shaking. The tubes
were washed with distilled water and dried at 85°C for 30 min. Lastly, 1 ml of a 80% ethanol-20% acetone
mixture was added for 15 min, to dissolve the CV stain. Samples were transferred to 96-well plates in
triplicate, and the OD595 was measured using an Inﬁnite 200 PRO plate reader (Tecan).
Motility assay. The motility of C. jejuni was determined as described previously, with a few
modiﬁcations (65). C. jejuni bacteria were grown on CBA plates at 37°C for 24 h, suspended in BHI broth,
and adjusted to an OD600 of 0.5, after which 1-l aliquots of the bacterial suspension were spotted onto
0.4% BHI soft agar plates. The low density of the agar allowed the bacteria to move within the agar,
forming a halo of growth around the point of inoculation. Plates were incubated for 3 days at 37°C under
microaerobic conditions.
Conjugation of C. jejuni. To generate the C. jejuni G1/pTet strain, the pTet plasmid from C. jejuni
81-176 was transferred to C. jejuni G1 by conjugation. A mixture of 200 l of the 81-176 donor strain with
100 l of the G1 recipient strain (MH medium inoculum at an OD600 of 1) was plated on top of a 0.22-m
ﬁlter membrane (Millipore), placed on the surface of a CBA plate, and incubated overnight at 37°C under
microaerobic conditions. The bacterial growth was scraped from the membrane and plated on CBA
supplemented with tetracycline (15 g/ml) and ampicillin (5 g/ml); the latter does not support the
growth of the 81-176 strain but allows the G1 strain to grow. PCR was conducted to conﬁrm the
derivative strain using the primers pTet-F (5=-GGCGTTTTGTTTATGTGCG-3=) and pTet-R (5=-ATGGACAAC
CCGACAGAAGC-3=).
Statistical analysis. All experiments were repeated three times (biological replicates), with three
technical replicates in each experiment, and the data were expressed as mean standard deviation (SD).
Comparisons of two groups were made with an unpaired, two-tailed, Student’s t test. Mean differences
were considered statistically nonsigniﬁcant when the P values were 0.05.
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